pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-101-1 |
Genomic Coordinates | chr1: 65058434 - 65058508 |
Description | Homo sapiens miR-101-1 stem-loop |
Comment | Reference . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-101-5p | ||||||||||||||||||
Sequence | 11| CAGUUAUCACAGUGCUGAUGCU |32 | ||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||
Experiments | Cloned | ||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ATM | ||||||||||||||||||||
Synonyms | AT1, ATA, ATC, ATD, ATDC, ATE, TEL1, TELO1 | ||||||||||||||||||||
Description | ATM serine/threonine kinase | ||||||||||||||||||||
Transcript | NM_000051 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ATM | |||||||||||||||||||||
3'UTR of ATM (miRNA target sites are highlighted) |
>ATM|NM_000051|3'UTR 1 TCTTCAGTATATGAATTACCCTTTCATTCAGCCTTTAGAAATTATATTTTAGCCTTTATTTTTAACCTGCCAACATACTT 81 TAAGTAGGGATTAATATTTAAGTGAACTATTGTGGGTTTTTTTGAATGTTGGTTTTAATACTTGATTTAATCACCACTCA 161 AAAATGTTTTGATGGTCTTAAGGAACATCTCTGCTTTCACTCTTTAGAAATAATGGTCATTCGGGCTGGGCGCAGCGGCT 241 CACGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGTGAGCGGATCACAAGGTCAGGAGTTCGAGACCAGCCTGGCCAAGA 321 GACCAGCCTGGCCAGTATGGTGAAACCCTGTCTCTACTAAAAATACAAAAATTAGCCGAGCATGGTGGCGGGCACCTGTA 401 ATCCCAGCTACTCGAGAGGCTGAGGCAGGAGAATCTCTTGAACCTGGGAGGTGAAGGTTGCTGTGGGCCAAAATCATGCC 481 ATTGCACTCCAGCCTGGGTGACAAGAGCGAAACTCCATCTCAAAAAAAAAAAAAAAAAAACAGAAACGTATTTGGATTTT 561 TCCTAGTAAGATCACTCAGTGTTACTAAATAATGAAGTTGTTATGGAGAACAAATTTCAAAGACACAGTTAGTGTAGTTA 641 CTATTTTTTTAAGTGTGTATTAAAACTTCTCATTCTATTCTCTTTATCTTTTAAGCCCTTCTGTACTGTCCATGTATGTT 721 ATCTTTCTGTGATAACTTCATAGATTGCCTTCTAGTTCATGAATTCTCTTGTCAGATGTATATAATCTCTTTTACCCTAT 801 CCATTGGGCTTCTTCTTTCAGAAATTGTTTTTCATTTCTAATTATGCATCATTTTTCAGATCTCTGTTTCTTGATGTCAT 881 TTTTAATGTTTTTTTAATGTTTTTTATGTCACTAATTATTTTAAATGTCTGTACTTGATAGACACTGTAATAGTTCTATT 961 AAATTTAGTTCCTGCTGTTTATATCTGTTGATTTTTGTATTTGATAGGCTGTTCATCCAGTTTTGTCTTTTTGAAAAGTG 1041 AGTTTATTTTCAGCAAGGCTTTATCTATGGGAATCTTGAGTGTCTGTTTATGTCATATTCCCAGGGCTGTTGCTGCACAC 1121 AAGCCCATTCTTATTTTAATTTCTTGGCTTTAGGGTTTCCATACCTGAAGTGTAGCATAAATACTGATAGGAGATTTCCC 1201 AGGCCAAGGCAAACACACTTCCTCCTCATCTCCTTGTGCTAGTGGGCAGAATATTTGATTGATGCCTTTTTCACTGAGAG 1281 TATAAGCTTCCATGTGTCCCACCTTTATGGCAGGGGTGGAAGGAGGTACATTTAATTCCCACTGCCTGCCTTTGGCAAGC 1361 CCTGGGTTCTTTGCTCCCCATATAGATGTCTAAGCTAAAAGCCGTGGGTTAATGAGACTGGCAAATTGTTCCAGGACAGC 1441 TACAGCATCAGCTCACATATTCACCTCTCTGGTTTTTCATTCCCCTCATTTTTTTCTGAGACAGAGTCTTGCTCTGTCAC 1521 CCAGGCTGGAGTGCAGTGGCATGATCTCAGCTCACTGAAACCTCTGCCTCCTGGGTTCAAGCAATTCTCCTGCCTCAGCC 1601 TCCCGAGTAGCTGGGACTACAGGCGTGTGCCAACACGCCCGGCTAATTTTTTGTATTTTTATTAGAGACGGAGTTTCACC 1681 GTGTTAGCCAGGATGGTCTCGATCGCTTGACCTCGTGATCCACCCTCCTCGGCCTCCCAAAGTGCTGGGATTACAGGTGT 1761 GAGCCACCGCGCCCGGCCTCATTCCCCTCATTTTTGACCGTAAGGATTTCCCCTTTCTTGTAAGTTCTGCTATGTATTTA 1841 AAAGAATGTTTTCTACATTTTATCCAGCATTTCTCTGTGTTCTGTTGGAAGGGAAGGGCTTAGGTATCTAGTTTGATACA 1921 TAGGTAGAAGTGGAACATTTCTCTGTCCCCCAGCTGTCATCATATAAGATAAACATCAGATAAAAAGCCACCTGAAAGTA 2001 AAACTACTGACTCGTGTATTAGTGAGTATAATCTCTTCTCCATCCTTAGGAAAATGTTCATCCCAGCTGCGGAGATTAAC 2081 AAATGGGTGATTGAGCTTTCTCCTCGTATTTGGACCTTGAAGGTTATATAAATTTTTTTCTTATGAAGAGTTGGCATTTC 2161 TTTTTATTGCCAATGGCAGGCACTCATTCATATTTGATCTCCTCACCTTCCCCTCCCCTAAAACCAATCTCCAGAACTTT 2241 TTGGACTATAAATTTCTTGGTTTGACTTCTGGAGAACTGTTCAGAATATTACTTTGCATTTCAAATTACAAACTTACCTT 2321 GGTGTATCTTTTTCTTACAAGCTGCCTAAATGAATATTTGGTATATATTGGTAGTTTTATTACTATAGTAAATCAAGGAA 2401 ATGCAGTAAACTTAAAATGTCTTTAAGAAAGCCCTGAAATCTTCATGGGTGAAATTAGAAATTATCAACTAGATAATAGT 2481 ATAGATAAATGAATTTGTAGCTAATTCTTGCTAGTTGTTGCATCCAGAGAGCTTTGAATAACATCATTAATCTACTCTTT 2561 AGCCTTGCATGGTATGCTATGAGGCTCCTGTTCTGTTCAAGTATTCTAATCAATGGCTTTGAAAAGTTTATCAAATTTAC 2641 ATACAGATCACAAGCCTAGGAGAAATAACTAATTCACAGATGACAGAATTAAGATTATAAAAGATTTTTTTTTTGTAATT 2721 TTAGTAGAGACAGGGTTGCCATTGTATTCCAGCCTTGGCGACAGAGCAAGACTCTGCCTCAAAAAAAAAAAAAAAAAGGT 2801 TTTGGCAAGCTGGAACTCTTTCTGCAAATGACTAAGATAGAAAACTGCCAAGGACAAATGAGGAGTAGTTAGATTTTGAA 2881 AATATTAATCATAGAATAGTTGTTGTATGCTAAGTCACTGACCCATATTATGTACAGCATTTCTGATCTTTACTTTGCAA 2961 GATTAGTGATACTATCCCAATACACTGCTGGAGAAATCAGAATTTGGAGAAATAAGTTGTCCAAGGCAAGAAGATAGTAA 3041 ATTATAAGTACAAGTGTAATATGGACAGTATCTAACTTGAAAAGATTTCAGGCGAAAAGAATCTGGGGTTTGCCAGTCAG 3121 TTGCTCAAAAGGTCAATGAAAACCAAATAGTGAAGCTATCAGAGAAGCTAATAAATTATAGACTGCTTGAACAGTTGTGT 3201 CCAGATTAAGGGAGATAATAGCTTTCCCACCCTACTTTGTGCAGGTCATACCTCCCCAAAGTGTTTACCTAATCAGTAGG 3281 TTCACAAACTCTTGGTCATTATAGTATATGCCTAAAATGTATGCACTTAGGAATGCTAAAAATTTAAATATGGTCTAAAG 3361 CAAATAAAAGCAAAGAGGAAAAACTTTGGACAGCGTAAAGACTAGAATAGTCTTTTAAAAAGAAAGCCAGTATATTGGTT 3441 TGAAATATAGAGATGTGTCCCAATTTCAAGTATTTTAATTGCACCTTAATGAAATTATCTATTTTCTATAGATTTTAGTA 3521 CTATTGAATGTATTACTTTACTGTTACCTGAATTTATTATAAAGTGTTTTTGAATAAATAATTCTAAAAGC Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | 293T , 95C , 95D , U87MGD , U87MG , M059K |
Disease | AGCTATGAAGTTATCACAGAAAGATAACATA; |
Location of target site | 3'UTR |
Tools used in this research | MicroCosm , miRanda , miRBase Target Database |
Original Description (Extracted from the article) |
...
"We identified that miR- 101 could efficiently target DNA-PKcs and ATM via binding to the 3'- UTR of DNA-PKcs or ATM mRNA.//To verify whether DNA-PKcs or ATM is a target of miR-101
... - Yan D; Ng WL; Zhang X; Wang P; Zhang Z; Mo et al., 2010, PloS one. |
Article |
- Yan D; Ng WL; Zhang X; Wang P; Zhang Z; Mo et al. - PloS one, 2010
BACKGROUND: Radiotherapy kills tumor-cells by inducing DNA double strand breaks (DSBs). However, the efficient repair of tumors frequently prevents successful treatment. Therefore, identifying new practical sensitizers is an essential step towards successful radiotherapy. In this study, we tested the new hypothesis: identifying the miRNAs to target DNA DSB repair genes could be a new way for sensitizing tumors to ionizing radiation. PRINCIPAL FINDINGS: HERE, WE CHOSE TWO GENES: DNA-PKcs (an essential factor for non-homologous end-joining repair) and ATM (an important checkpoint regulator for promoting homologous recombination repair) as the targets to search their regulating miRNAs. By combining the database search and the bench work, we picked out miR-101. We identified that miR-101 could efficiently target DNA-PKcs and ATM via binding to the 3'- UTR of DNA-PKcs or ATM mRNA. Up-regulating miR-101 efficiently reduced the protein levels of DNA-PKcs and ATM in these tumor cells and most importantly, sensitized the tumor cells to radiation in vitro and in vivo. CONCLUSIONS: These data demonstrate for the first time that miRNAs could be used to target DNA repair genes and thus sensitize tumors to radiation. These results provide a new way for improving tumor radiotherapy.
LinkOut: [PMID: 20617180]
|
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
63 hsa-miR-101-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT005558 | PRKDC | protein kinase, DNA-activated, catalytic polypeptide | 2 | 1 | ||||||||
MIRT005559 | ATM | ATM serine/threonine kinase | 3 | 1 | ||||||||
MIRT038714 | TMSB10 | thymosin beta 10 | 1 | 1 | ||||||||
MIRT064840 | ZBTB18 | zinc finger and BTB domain containing 18 | 2 | 2 | ||||||||
MIRT066165 | PIP4K2C | phosphatidylinositol-5-phosphate 4-kinase type 2 gamma | 2 | 2 | ||||||||
MIRT089580 | MAT2A | methionine adenosyltransferase 2A | 2 | 4 | ||||||||
MIRT095008 | AFF4 | AF4/FMR2 family member 4 | 2 | 2 | ||||||||
MIRT266193 | TXNIP | thioredoxin interacting protein | 2 | 2 | ||||||||
MIRT280282 | CMPK1 | cytidine/uridine monophosphate kinase 1 | 2 | 2 | ||||||||
MIRT329427 | C5ORF51 | chromosome 5 open reading frame 51 | 2 | 2 | ||||||||
MIRT331963 | TEAD1 | TEA domain transcription factor 1 | 2 | 2 | ||||||||
MIRT333607 | EFHD2 | EF-hand domain family member D2 | 2 | 2 | ||||||||
MIRT355843 | AIMP1 | aminoacyl tRNA synthetase complex interacting multifunctional protein 1 | 2 | 2 | ||||||||
MIRT447684 | MTPAP | mitochondrial poly(A) polymerase | 2 | 2 | ||||||||
MIRT451781 | USP36 | ubiquitin specific peptidase 36 | 2 | 2 | ||||||||
MIRT452204 | TMEM68 | transmembrane protein 68 | 2 | 4 | ||||||||
MIRT465575 | TNRC6B | trinucleotide repeat containing 6B | 2 | 2 | ||||||||
MIRT466445 | TFAM | transcription factor A, mitochondrial | 2 | 8 | ||||||||
MIRT466769 | SYNCRIP | synaptotagmin binding cytoplasmic RNA interacting protein | 2 | 8 | ||||||||
MIRT470377 | PPP2R5E | protein phosphatase 2 regulatory subunit B'epsilon | 2 | 2 | ||||||||
MIRT471684 | PABPN1 | poly(A) binding protein nuclear 1 | 2 | 2 | ||||||||
MIRT480906 | BCL2L2-PABPN1 | BCL2L2-PABPN1 readthrough | 2 | 2 | ||||||||
MIRT491030 | FDX1 | ferredoxin 1 | 2 | 4 | ||||||||
MIRT506124 | PMAIP1 | phorbol-12-myristate-13-acetate-induced protein 1 | 2 | 8 | ||||||||
MIRT506610 | MARCH6 | membrane associated ring-CH-type finger 6 | 2 | 8 | ||||||||
MIRT520592 | TMEM55B | phosphatidylinositol-4,5-bisphosphate 4-phosphatase 1 | 2 | 6 | ||||||||
MIRT531128 | CLPB | ClpB homolog, mitochondrial AAA ATPase chaperonin | 2 | 2 | ||||||||
MIRT532220 | CCDC117 | coiled-coil domain containing 117 | 2 | 2 | ||||||||
MIRT532787 | RBM22 | RNA binding motif protein 22 | 2 | 2 | ||||||||
MIRT535709 | NAA50 | N(alpha)-acetyltransferase 50, NatE catalytic subunit | 2 | 2 | ||||||||
MIRT539026 | ATXN7L1 | ataxin 7 like 1 | 2 | 4 | ||||||||
MIRT540298 | TMA16 | translation machinery associated 16 homolog | 2 | 2 | ||||||||
MIRT547194 | PAWR | pro-apoptotic WT1 regulator | 2 | 2 | ||||||||
MIRT548935 | CDK17 | cyclin dependent kinase 17 | 2 | 2 | ||||||||
MIRT550033 | WWTR1 | WW domain containing transcription regulator 1 | 2 | 2 | ||||||||
MIRT552244 | DUSP3 | dual specificity phosphatase 3 | 2 | 2 | ||||||||
MIRT553557 | TMEM161B | transmembrane protein 161B | 2 | 2 | ||||||||
MIRT555067 | PXK | PX domain containing serine/threonine kinase like | 2 | 2 | ||||||||
MIRT555493 | PNRC2 | proline rich nuclear receptor coactivator 2 | 2 | 2 | ||||||||
MIRT555824 | PAX9 | paired box 9 | 2 | 2 | ||||||||
MIRT556614 | LCOR | ligand dependent nuclear receptor corepressor | 2 | 2 | ||||||||
MIRT559225 | BLMH | bleomycin hydrolase | 2 | 2 | ||||||||
MIRT560200 | GXYLT2 | glucoside xylosyltransferase 2 | 2 | 2 | ||||||||
MIRT568262 | BMP2K | BMP2 inducible kinase | 2 | 2 | ||||||||
MIRT573847 | PPA1 | pyrophosphatase (inorganic) 1 | 2 | 2 | ||||||||
MIRT609581 | GJD2 | gap junction protein delta 2 | 2 | 2 | ||||||||
MIRT609940 | MYCBP | MYC binding protein | 2 | 2 | ||||||||
MIRT627026 | CREBL2 | cAMP responsive element binding protein like 2 | 2 | 2 | ||||||||
MIRT679122 | NMNAT1 | nicotinamide nucleotide adenylyltransferase 1 | 2 | 2 | ||||||||
MIRT685557 | TXK | TXK tyrosine kinase | 2 | 2 | ||||||||
MIRT686204 | ZNF451 | zinc finger protein 451 | 2 | 2 | ||||||||
MIRT694309 | COPB2 | coatomer protein complex subunit beta 2 | 2 | 2 | ||||||||
MIRT698793 | STK38 | serine/threonine kinase 38 | 2 | 2 | ||||||||
MIRT702499 | KIAA0040 | KIAA0040 | 2 | 2 | ||||||||
MIRT716978 | GTDC1 | glycosyltransferase like domain containing 1 | 2 | 2 | ||||||||
MIRT734345 | PVT1 | Pvt1 oncogene (non-protein coding) | 0 | 0 | ||||||||
MIRT734346 | MALAT1 | metastasis associated lung adenocarcinoma transcript 1 (non-protein coding) | 0 | 0 | ||||||||
MIRT735948 | COL10A1 | collagen type X alpha 1 chain | 3 | 0 | ||||||||
MIRT735950 | COL12A1 | collagen type XII alpha 1 chain | 3 | 0 | ||||||||
MIRT735954 | TGFBR1 | transforming growth factor beta receptor 1 | 3 | 0 | ||||||||
MIRT737208 | GINS1 | GINS complex subunit 1 | 2 | 0 | ||||||||
MIRT737457 | DONSON | downstream neighbor of SON | 4 | 0 | ||||||||
MIRT756268 | DUSP6 | dual specificity phosphatase 6 | 3 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|